For example, patients with recurrent CLL acquire the BCL-2 Gly101Val and BCL-2 Asp103Glu mutations during venetoclax treatment, which seriously affects their prognosis [43]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.